Andrx Completes Lovastatin XL Studies.

Business Editors/Health & Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Nov. 13, 2000

ANDRX CORPORATION--ANDRX GROUP (Nasdaq:ADRX) announced today that it has completed the pivotal Phase III trials for Lovastatin XL, its first brand product. The initial analyses of these studies indicates that Lovastatin XL's efficacy is similar to those of other potent HMG-CoA reductase inhibitors, with a majority of patients achieving therapeutic goals on the projected starting dose. Lovastatin XL was generally well tolerated and no unexpected safety concerns were identified. Andrx anticipates that it will file a New Drug Application with the United States Food and Drug Administration for its product in the first quarter of 2001.

Based on results from the Phase III studies, Andrx has initiated additional new studies with the aim of extending the usages for Lovastatin XL. Initial results from these studies are expected in the first quarter of 2001.

Andrx Chief Executive Officer, Alan P. Cohen, commented, "We are pleased that our first NDA project is progressing as planned with the results of our trials in line with expectations. Andrx believes Lovastatin XL will offer an important treatment option for patients with dyslipidemia at risk for cardiovascular disease."

Lovastatin XL utilizes Andrx' SCOT technology and was designed to provide extended delivery of drug, especially to the liver, the site of cholesterol biosynthesis. Andrx has both an issued patent and a pending patent application relating to this product.

Andrx has other products under development in its NDA program, including Metformin XT, which is in Phase III clinical trials in over 50 centers in the U.S.

Andrx is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, Andrx is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of Andrx Corporation's drug delivery technologies. Andrx also markets and distributes pharmaceutical products manufactured by third parties. Andrx Corporation's Cybear Group (Nasdaq:CYBA) intends to use the Internet to improve the efficiency of administrative and communications tasks of managing patient care - while addressing the healthcare industry's critical need for secure and reliable transmission of information.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties. Andrx is a class of common stock of Andrx Corporation, therefore Andrx Corporation shareholders are subject to the risks and uncertainties described in Andrx Corporation's filings with the Securities and Exchange Commission, including Andrx Corporation's Annual Report on Form 10-K for the year ended December 31, 1999.

This release and additional information about Andrx Group and Andrx Corporation also available on the Internet at: http://www.andrx.com.